
Novo Nordisk plans $1bn Brazil expansion
The Danish pharmaceutical company behind obesity drug Wegovy, Novo Nordisk, plans to invest US$1.09bn in expanding its facility in Minas Gerais, southeast Brazil. The 74,000-sq-m project will be used for multiple products, including the GLP-1 hormone used …